Literature DB >> 33213800

Best Practices in Surveillance for Barrett's Esophagus.

Joseph R Triggs1, Gary W Falk2.   

Abstract

Barrett's esophagus is the precursor lesion for esophageal adenocarcinoma. The goals of endoscopic surveillance are to detect dysplasia and early esophageal adenocarcinoma in order to improve patient outcomes. Despite the ongoing debate regarding the efficacy of surveillance, all current gastrointestinal societies recommend surveillance at this time. Optimal surveillance technique includes adequate inspection time, evaluation using high-definition white light and chromoendoscopy, appropriate documentation of the metaplastic segment using the Prague C & M criteria as well as the Paris classification should lesions be found, utilization of the Seattle biopsy protocol, and endoscopic resection of visible lesions.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Barrett's esophagus; Dysplasia; Esophageal adenocarcinoma; Intestinal metaplasia; Surveillance

Mesh:

Year:  2020        PMID: 33213800      PMCID: PMC7684982          DOI: 10.1016/j.giec.2020.08.003

Source DB:  PubMed          Journal:  Gastrointest Endosc Clin N Am        ISSN: 1052-5157


  97 in total

1.  The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on imaging in Barrett's Esophagus.

Authors:  Prateek Sharma; Thomas J Savides; Marcia I Canto; Douglas A Corley; Gary W Falk; John R Goldblum; Kenneth K Wang; Michael B Wallace; Herbert C Wolfsen
Journal:  Gastrointest Endosc       Date:  2012-08       Impact factor: 9.427

2.  Circumferential location predicts the risk of high-grade dysplasia and early adenocarcinoma in short-segment Barrett's esophagus.

Authors:  Viraj C Kariyawasam; Michael J Bourke; Luke F Hourigan; Gary Lim; Alan Moss; Stephen J Williams; Scott B Fanning; Adrian M Chung; Karen Byth
Journal:  Gastrointest Endosc       Date:  2012-03-03       Impact factor: 9.427

3.  Acetic acid-enhanced chromoendoscopy is more cost-effective than protocol-guided biopsies in a high-risk Barrett's population.

Authors:  P Bhandari; P Kandaswamy; D Cowlishaw; G Longcroft-Wheaton
Journal:  Dis Esophagus       Date:  2011-10-07       Impact factor: 3.429

Review 4.  Pathogenesis and Cells of Origin of Barrett's Esophagus.

Authors:  Jianwen Que; Katherine S Garman; Rhonda F Souza; Stuart Jon Spechler
Journal:  Gastroenterology       Date:  2019-05-10       Impact factor: 22.682

5.  Endoscopists systematically undersample patients with long-segment Barrett's esophagus: an analysis of biopsy sampling practices from a quality improvement registry.

Authors:  Sachin Wani; J Lucas Williams; Srinadh Komanduri; V Raman Muthusamy; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2019-05-11       Impact factor: 9.427

6.  The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis.

Authors:  Tusar K Desai; Kumar Krishnan; Niharika Samala; Jashanpreet Singh; John Cluley; Subaiah Perla; Colin W Howden
Journal:  Gut       Date:  2011-10-13       Impact factor: 23.059

Review 7.  Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Palaniappan Manickam; Anita V Amin; Niharika Samala; Leo J Schouten; Prasad G Iyer; Tusar K Desai
Journal:  Gastrointest Endosc       Date:  2014-02-17       Impact factor: 9.427

8.  High definition versus standard definition white light endoscopy for detecting dysplasia in patients with Barrett's esophagus.

Authors:  S S Sami; V Subramanian; W M Butt; G Bejkar; J Coleman; J Mannath; K Ragunath
Journal:  Dis Esophagus       Date:  2014-09-10       Impact factor: 3.429

Review 9.  The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Fouad Yousef; Chris Cardwell; Marie M Cantwell; Karen Galway; Brian T Johnston; Liam Murray
Journal:  Am J Epidemiol       Date:  2008-06-12       Impact factor: 4.897

10.  Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus.

Authors:  Jon M Davison; John Goldblum; Udhayvir Singh Grewal; Kevin McGrath; Kenneth Fasanella; Christopher Deitrick; Aaron D DeWard; Emily A Bossart; Stephen L Hayward; Yi Zhang; Rebecca J Critchley-Thorne; Prashanthi N Thota
Journal:  Am J Gastroenterol       Date:  2020-06       Impact factor: 12.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.